Skip to main content

Table 1 Demographic and clinicopathologic characteristics of non-metastatic nasopharyngeal carcinoma patients in the training set, internal validation set, and IMRT cohort

From: Development and validation of a nomogram for predicting the survival of patients with non-metastatic nasopharyngeal carcinoma after curative treatment

Variable Primary cohort [cases (%)] IMRT cohort [cases (%)]
Total Training set Validation set
Total 1520 1216 304 464
Sex
 Male 1161 (76.4) 922 (75.8) 239 (78.6) 361 (77.8)
 Female 359 (23.6) 294 (24.2) 65 (21.4) 103 (22.2)
Age (years)
 <50 977 (64.3) 769 (63.2) 208 (68.4) 345 (74.4)
 ≥50 543 (35.7) 447 (36.8) 96 (31.6) 119 (25.6)
Smoking history
 No 789 (51.9) 630 (51.8) 159 (52.3) 271 (58.4)
 Yes 731 (48.1) 586 (48.2) 145 (47.7) 193 (41.6)
Alcohol consumption
 No 1282 (84.3) 1030 (84.7) 252 (82.9) 387 (83.4)
 Yes 238 (15.7) 186 (15.3) 52 (17.1) 77 (16.6)
BMI (kg/m2)
 >26 210 (13.8) 174 (14.3) 36 (11.8) 150 (32.3)
 20–26 949 (62.4) 755 (62.1) 194 (63.8) 312 (67.2)
 <20 361 (23.8) 287 (23.6) 74 (24.3) 2 (0.4)
Hemoglobin level (g/L)
 >150 498 (32.8) 399 (32.8) 99 (32.6) 186 (40.1)
 ≤150 1022 (67.2) 817 (67.2) 205 (67.4) 278 (59.9)
NLR
 <3.5 1129 (74.3) 906 (74.5) 223 (73.4) 384 (82.8)
 ≥3.5 391 (25.7) 310 (25.5) 81 (26.6) 80 (17.2)
Platelet count (×109/L)
 <300 1251 (82.3) 1000 (82.2) 251 (82.6) 408 (87.9)
 ≥300 269 (17.7) 216 (17.8) 53 (17.4) 56 (12.1)
LDH level (U/L)
 <190 897 (59.0) 717 (59.0) 180 (59.2) 352 (75.9)
 190–240 399 (26.3) 315 (25.9) 84 (27.6) 80 (17.2)
 >240 224 (14.7) 184 (15.1) 40 (13.2) 32 (6.9)
ALP level (U/L)
 <90 1227 (80.7) 978 (80.4) 249 (81.9) 401 (86.4)
 ≥90 293 (19.3) 238 (19.6) 55 (18.1) 63 (13.6)
Histological type
 WHO I 6 (0.4) 5 (0.4) 1 (0.3) 1 (0.2)
 WHO II 102 (6.7) 78 (6.4) 24 (7.9) 41 (8.8)
 WHO III 1412 (92.9) 1133 (93.2) 279 (91.8) 422 (90.9)
T stage
 T1 262 (17.2) 198 (16.3) 64 (21.1) 86 (18.5)
 T2 746 (49.1) 603 (49.6) 143 (47.0) 119 (25.6)
 T3 267 (17.6) 213 (17.5) 54 (17.8) 191 (41.2)
 T4 245 (16.1) 202 (16.6) 43 (14.1) 68 (14.7)
N stage
 N0 419 (27.6) 337 (27.7) 82 (27.0) 116 (25.0)
 N1 642 (42.2) 510 (41.9) 132 (43.4) 193 (41.6)
 N2 408 (26.8) 326 (26.8) 82 (27.0) 144 (31.0)
 N3 51 (3.4) 43 (3.5) 8 (2.6) 11 (2.4)
TNM stage
 I 79 (5.2) 60 (4.9) 19 (6.3) 43 (9.3)
 II 638 (42.0) 511 (42.0) 127 (41.8) 113 (24.4)
 III 515 (33.9) 408 (33.6) 107 (35.2) 231 (49.8)
 IV 288 (18.9) 237 (19.5) 51 (16.8) 77 (16.6)
VCA-IgA titer
 <1:1280 1275 (83.9) 1013 (83.3) 262 (86.2) 420 (90.5)
 ≥1:1280 245 (16.1) 203 (16.7) 42 (13.8) 44 (9.5)
EA-IgA
 Negative 334 (22.0) 272 (22.4) 62 (20.4) 127 (27.4)
 >0 1186 (78.0) 944 (77.6) 242 (79.6) 337 (72.6)
Anti-DNase (%)
 ≤50 516 (33.9) 407 (33.5) 109 (35.9) 221 (47.6)
 >50 1004 (66.1) 809 (66.5) 195 (64.1) 205 (44.2)a
Neoadjuvant chemotherapy
 Yes 997 (65.6) 800 (65.8) 197 (64.8) 304 (65.5)
 No 523 (34.4) 416 (34.2) 107 (35.2) 160 (34.5)
Concomitant chemotherapy
 Yes 1171 (77.0) 933 (76.7) 238 (78.3) 145 (31.3)
 No 349 (23.0) 283 (23.3) 66 (21.7) 319 (68.7)
Adjuvant chemotherapy
 Yes 1513 (99.5) 1210 (99.5) 303 (99.7) 445 (95.9)
 No 7 (0.5) 6 (0.5) 1 (0.3) 19 (4.1)
Radiation dose (Gy)
 ≤75 1329 (87.4) 1059 (87.1) 270 (88.8) 240 (51.7)
 >75 191 (12.6) 157 (12.9) 34 (11.2) 224 (48.3)
  1. IMRT intensity-modulated radiation therapy; BMI body mass index; NLR neutrophil–lymphocyte ratio; LDH lactate dehydrogenase; ALP alkaline phosphatase; WHO World Health Organization; VCA-IgA immunoglobulin A against Epstein–Barr virus viral capsid antigen; EA-IgA immunoglobulin A against Epstein–Barr virus viral early antigen
  2. aThe data of 38 patients were missing
\